Oncolytics Biotech Starts Patient Treatment in UK Phase I Cancer Trial Investigating Systemic Delivery of REOLYSIN(R)

28-May-2004

Calgary - Oncolytics Biotech Inc. ("Oncolytics") announced that it has started patient treatment in its UK Phase I clinical trial investigating the systemic delivery of REOLYSIN(R) as a treatment for patients with advanced or metastatic solid tumours.

This clinical trial is an open-label, dose-escalation Phase I study in which REOLYSIN(R) will be administered intravenously to patients diagnosed with advanced or metastatic solid tumours that are refractory to standard therapy (have not responded) or for which no curative standard therapy exists. The primary objective of the study is to determine the maximum tolerated dose (MTD), dose limiting toxicity (DLT) and safety profile of REOLYSIN(R). Secondary objectives include the evaluation of viral replication, immune response to the virus and any evidence of antitumour activity. The enrolment in this study is expected to be up to forty evaluable patients and will depend upon the number of dose levels tested. The principal investigator for the study is Dr. J. de Bono of the Royal Marsden Hospital.

Other news from the department science

Most read news

More news from our other portals

So close that even
molecules turn red...

Last viewed contents

AMRI Announces Strategic Contract with Knopp Biosciences

Kinaxo Starts Collaboration with Roche in the Field of Phosphoproteomics

Chemokine Therapeutics Receives Approval From Hong Kong to Commence Phase II Study in Liver Cancer

New tool for studying magnetic, self-propelled bacteria that resemble compass needles

New tool for studying magnetic, self-propelled bacteria that resemble compass needles

New Biomedical Sciences Executive Committee Established to Lead Phase 2 of Singapore's Biomedical Sciences Initiative

EHEC O104:H4 outbreak event in Germany clarified: sprouts of fenugreek seeds imported from Egypt as underlying cause

Rheumatoid arthritis signaling protein reverses Alzheimer's disease in mouse model - New study shows GM-CSF reduces AD pathology and eliminates memory loss

Aastrom Biosciences and Zellera AG Announce the Initiation of a Clinical Trial for Bone Grafting in Spain - Aastrom's Proprietary TRCs to be Utilized in Second European Clinical Study to Treat Major Bone Fractures

Chemokine Therapeutics achieves critical milestone with the start of a phase Ib/II human clinical trial in cancer

Positive Phase II preliminary results of Validive for the prevention of Severe Oral Mucositis in Head and Neck cancer patients - Improved oral mucositis related symptoms and decreased adverse events related to radiotherapy

Fight against antibiotic-resistant bacteria has a glowing new weapon - A new chemical probe signaling antibiotic resistance risk

Fight against antibiotic-resistant bacteria has a glowing new weapon - A new chemical probe signaling antibiotic resistance risk